Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 8/20 | 0.59 |
| ▸ | FYN | P06241 | 3/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | HCK | P08631 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30560046 | 1.00 | DHFR (0.59) | DHFRFYNLCKHCKSRC | |
| SCHEMBL14694265 | 0.85 | DHFR (0.58) | DHFRKDM4EALDH1A1GAAMAPT | |
| SCHEMBL2558872 | 0.84 | DHFR (0.60) | DHFRFYN | |
| SCHEMBL29019905 | 0.83 | DHFR (0.52) | DHFRFYNHRH4KDM4EALDH1A1 | |
| SCHEMBL17907560 | 0.83 | DHFR (0.56) | DHFR | |
| SCHEMBL30515653 | 0.83 | DHFR (0.56) | DHFR | |
| SCHEMBL28070389 | 0.80 | HRH4 (0.52) | DHFRFYNLCKHCKSRC | |
| SCHEMBL17907568 | 0.80 | LMNA (0.54) | DHFR | |
| SCHEMBL29213517 | 0.78 | PTK2 (0.49) | DHFRFYNLCKHCKSRC | |
| SCHEMBL30827032 | 0.78 | PTK2 (0.49) | DHFRFYNLCKHCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951684-B1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2016-07-13 | — | — | EP | disclosed |
| EP-2968331-A1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | Icahn School of Medicine at Mount Sinai (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151682-A1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2014-09-25 | — | — | WO | disclosed |
| CN-101370792-B | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN INC | 2013-03-20 | — | — | CN | disclosed |
| EP-2558474-A1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| WO-2011130390-A1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| CN-101370792-A | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN INC (US) | 2009-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | DHFR 227/4885FYN 221/4885LCK 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.